{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:58:22Z","timestamp":1784735902701,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T00:00:00Z","timestamp":1685145600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Avadel Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s12325-023-02532-y","type":"journal-article","created":{"date-parts":[[2023,5,27]],"date-time":"2023-05-27T10:02:13Z","timestamp":1685181733000},"page":"3199-3216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment"],"prefix":"10.1007","volume":"40","author":[{"given":"Anne Marie","family":"Morse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Krahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Flygare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clete","family":"Kushida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Thorpy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amod","family":"Athavale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gudeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,27]]},"reference":[{"issue":"9560","key":"2532_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","volume":"369","author":"Y Dauvilliers","year":"2007","unstructured":"Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet. 2007;369(9560):499\u2013511.","journal-title":"Lancet"},{"issue":"1","key":"2532_CR2","doi-asserted-by":"publisher","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","volume":"3","author":"BR Kornum","year":"2017","unstructured":"Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3(1):16100.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"2532_CR3","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.sleep.2012.08.002","volume":"13","author":"F Ingravallo","year":"2012","unstructured":"Ingravallo F, Gnucci V, Pizza F, et al. The burden of narcolepsy with cataplexy: how disease history and clinical features influence socio-economic outcomes. Sleep Med. 2012;13(10):1293\u2013300.","journal-title":"Sleep Med"},{"issue":"3","key":"2532_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13210","volume":"30","author":"TE Weaver","year":"2021","unstructured":"Weaver TE, Mathias SD, Crosby RD, et al. Relationship between sleep efficacy endpoints and measures of functional status and health-related quality of life in participants with narcolepsy or obstructive sleep apnea treated for excessive daytime sleepiness. J Sleep Res. 2021;30(3): e13210.","journal-title":"J Sleep Res"},{"issue":"27","key":"2532_CR5","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1056\/NEJMra1500587","volume":"373","author":"TE Scammell","year":"2015","unstructured":"Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654\u201362.","journal-title":"N Engl J Med"},{"issue":"1","key":"2532_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","volume":"16","author":"MJ Thorpy","year":"2015","unstructured":"Thorpy MJ, Dauvilliers Y. Clinical and practical considerations in the pharmacologic management of narcolepsy. Sleep Med. 2015;16(1):9\u201318.","journal-title":"Sleep Med"},{"issue":"1","key":"2532_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40263-019-00689-1","volume":"34","author":"MJ Thorpy","year":"2020","unstructured":"Thorpy MJ. Recently approved and upcoming treatments for narcolepsy. CNS Drugs. 2020;34(1):9\u201327.","journal-title":"CNS Drugs"},{"key":"2532_CR8","unstructured":"XYREM (sodium oxybate oral solution, CIII). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals; 2022."},{"key":"2532_CR9","unstructured":"XYWAV (calcium, magnesium, potassium, and sodium oxybates oral colution, CIII). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals; 2022."},{"key":"2532_CR10","unstructured":"Wakix (pitolisant). Full Prescribing Information. Plymouth Meeting: Harmony Biosciences, LLC; 2019."},{"issue":"9","key":"2532_CR11","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.5664\/jcsm.9328","volume":"17","author":"K Maski","year":"2021","unstructured":"Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881\u201393.","journal-title":"J Clin Sleep Med"},{"key":"2532_CR12","unstructured":"SUNOSI (solriamfetol). Full Prescribing Information. Palo Alto: Jazz Pharmaceuticals; 2019."},{"key":"2532_CR13","unstructured":"RITALIN (methylphenidate hydrochloride). Full Prescribing Information. East Hanover: Novartis Pharmaceuticals Corporation; 2019."},{"key":"2532_CR14","unstructured":"PROVIGIL (modafinil). Full Prescribing Information. North Wales: Teva Pharmaceuticals; 2015."},{"key":"2532_CR15","unstructured":"NUVIGIL (armodafinil). Full Prescribing Information. North Wales: Teva Pharmaceuticals, Inc.; 2017."},{"key":"2532_CR16","unstructured":"DEXEDRINE (dextroamphetamine sulfate). Full Prescribing Information. Horsham: Amedra Pharmaceuticals; 2013."},{"issue":"5","key":"2532_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","volume":"30","author":"L Barateau","year":"2016","unstructured":"Barateau L, Lopez R, Dauvilliers Y. Treatment options for narcolepsy. CNS Drugs. 2016;30(5):369\u201379.","journal-title":"CNS Drugs"},{"issue":"1","key":"2532_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-021-01051-4","volume":"18","author":"C Franceschini","year":"2021","unstructured":"Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of narcolepsy. Neurotherapeutics. 2021;18(1):6\u201319.","journal-title":"Neurotherapeutics"},{"issue":"2","key":"2532_CR19","first-page":"35","volume":"76","author":"R Peraita-Adrados","year":"2023","unstructured":"Peraita-Adrados R, Bellon JM, Lillo-Triguero L, Lopez-Esteban P, Medrano-Martinez P. Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1. Rev Neurol. 2023;76(2):35\u201340.","journal-title":"Rev Neurol"},{"issue":"7","key":"2532_CR20","first-page":"527","volume":"18","author":"CI Coleman","year":"2012","unstructured":"Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm. 2012;18(7):527\u201339.","journal-title":"J Manag Care Pharm"},{"key":"2532_CR21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2016.04.082","volume":"216","author":"ER Weeda","year":"2016","unstructured":"Weeda ER, Coleman CI, McHorney CA, Crivera C, Schein JR, Sobieraj DM. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. Int J Cardiol. 2016;216:104\u20139.","journal-title":"Int J Cardiol"},{"issue":"6","key":"2532_CR22","first-page":"e22","volume":"15","author":"SD Saini","year":"2009","unstructured":"Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22\u201333.","journal-title":"Am J Manag Care"},{"issue":"4","key":"2532_CR23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s40263-022-00904-6","volume":"36","author":"T Roth","year":"2022","unstructured":"Roth T, Dauvilliers Y, Thorpy MJ, et al. Effect of FT218, a once-nightly sodium oxybate formulation, on disrupted nighttime sleep in patients with narcolepsy: results from the randomized phase III REST-ON trial. CNS Drugs. 2022;36(4):377\u201387.","journal-title":"CNS Drugs"},{"issue":"6","key":"2532_CR24","doi-asserted-by":"publisher","first-page":"596","DOI":"10.5664\/jcsm.27994","volume":"6","author":"J Black","year":"2010","unstructured":"Black J, Pardi D, Hornfeldt CS, Inhaber N. The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med. 2010;6(6):596\u2013602.","journal-title":"J Clin Sleep Med"},{"issue":"12","key":"2532_CR25","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/sleep\/30.12.1705","volume":"30","author":"TI Morgenthaler","year":"2007","unstructured":"Morgenthaler TI, Kapur VK, Brown T, et al. Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007;30(12):1705\u201311.","journal-title":"Sleep"},{"key":"2532_CR26","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2147\/PPA.S353412","volume":"16","author":"J Dubow","year":"2022","unstructured":"Dubow J, Avidan AY, Corser B, Athavale A, Seiden D, Kushida C. Preferences for attributes of sodium oxybate treatment: a discrete choice experiment in patients with narcolepsy. Patient Prefer Adherence. 2022;16:937\u201347.","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"2532_CR27","doi-asserted-by":"publisher","first-page":"672.e1","DOI":"10.1016\/j.clinthera.2021.01.017","volume":"43","author":"D Seiden","year":"2021","unstructured":"Seiden D, Tyler C, Dubow J. Pharmacokinetics of FT218, a once-nightly sodium oxybate formulation in healthy adults. Clin Ther. 2021;43(4):672.e1\u2013672.e14.","journal-title":"Clin Ther"},{"key":"2532_CR28","unstructured":"Avadel Pharmaceuticals. Avadel Pharmaceuticals announces tentative approval of LUMRYZ\u2122 (Sodium Oxybate) extended-release oral suspension. 2022. https:\/\/investors.avadel.com\/news-releases\/news-release-details\/avadel-pharmaceuticals-announces-tentative-approval-lumryztm. Accessed 19 Jul 2022."},{"issue":"6","key":"2532_CR29","doi-asserted-by":"publisher","first-page":"zsab200","DOI":"10.1093\/sleep\/zsab200","volume":"45","author":"CA Kushida","year":"2022","unstructured":"Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):zsab200.","journal-title":"Sleep"},{"key":"2532_CR30","unstructured":"PROZAC (fluoxetine). Full prescribing information. Indianapolis: Eli Lilly and Company Pharmaceuticals; 2017."},{"key":"2532_CR31","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals, Inc. Release: Xyrem\u00ae receives FDA approval for the treatment of excessive daytime sleepiness in patients with narcolepsy. 2022. https:\/\/www.biospace.com\/article\/releases\/jazz-pharmaceuticals-inc-release-xyrem-r-receives-fda-approval-for-the-treatment-of-excessive-daytime-sleepiness-in-patients-with-narcolepsy-\/. Accessed 15 Jul 2022."},{"key":"2532_CR32","unstructured":"Jazz Pharmaceuticals. Jazz Pharmaceuticals Announces U.S. FDA approval of Xywav\u2122 (calcium, magnesium, potassium, and sodium oxybates) oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy. 2020. http:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-announces-us-fda-approval-xywavtm-calcium. Accessed 15 Oct 2020."},{"issue":"4","key":"2532_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313.","journal-title":"Value Health"},{"issue":"4","key":"2532_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1185\/03007995.2016.1142959","volume":"32","author":"M Heisen","year":"2016","unstructured":"Heisen M, Baeten SA, Verheggen BG, et al. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Curr Med Res Opin. 2016;32(4):787\u201396.","journal-title":"Curr Med Res Opin"},{"issue":"7248","key":"2532_CR35","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1136\/bmj.320.7248.1530","volume":"320","author":"M Ryan","year":"2000","unstructured":"Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320(7248):1530\u20133.","journal-title":"BMJ"},{"issue":"1","key":"2532_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13561-020-00276-x","volume":"10","author":"E van den Broek-Altenburg","year":"2020","unstructured":"van den Broek-Altenburg E, Atherly A. Using discrete choice experiments to measure preferences for hard to observe choice attributes to inform health policy decisions. Health Econ Rev. 2020;10(1):18.","journal-title":"Health Econ Rev"},{"key":"2532_CR37","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/1472-6963-14-235","volume":"14","author":"GA Abiiro","year":"2014","unstructured":"Abiiro GA, Leppert G, Mbera GB, Robyn PJ, De Allegri M. Developing attributes and attribute-levels for a discrete choice experiment on micro health insurance in rural Malawi. BMC Health Serv Res. 2014;14:235.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"2532_CR38","doi-asserted-by":"publisher","first-page":"zsaa206","DOI":"10.1093\/sleep\/zsaa206","volume":"44","author":"RK Bogan","year":"2021","unstructured":"Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206.","journal-title":"Sleep"},{"issue":"1","key":"2532_CR39","first-page":"42","volume":"25","author":"X. S. Xyrem Multicenter Study Group","year":"2002","unstructured":"X. S. Xyrem Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42\u20139.","journal-title":"Sleep"},{"issue":"2","key":"2532_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.sleep.2003.11.002","volume":"5","author":"U. S. Xyrem Multicenter Study Group","year":"2004","unstructured":"U. S. Xyrem Multicenter Study Group. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med. 2004;5(2):119\u201323.","journal-title":"Sleep Med"},{"issue":"7","key":"2532_CR41","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","volume":"29","author":"J Black","year":"2006","unstructured":"Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939\u201346.","journal-title":"Sleep"},{"key":"2532_CR42","unstructured":"Center for Drug Evaluation and Research (CDER). The Voice of the Patient: Narcolepsy. Silver Spring: US Food and Drug Administration; 2014."},{"issue":"9","key":"2532_CR43","doi-asserted-by":"publisher","first-page":"zsy128","DOI":"10.1093\/sleep\/zsy128","volume":"41","author":"G Mayer","year":"2018","unstructured":"Mayer G, Plazzi G, Iranzo A, et al. Long-term compliance, safety, and tolerability of sodium oxybate treatment in patients with narcolepsy type 1: a postauthorization, noninterventional surveillance study. Sleep. 2018;41(9):zsy128.","journal-title":"Sleep"},{"key":"2532_CR44","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.sleep.2020.02.013","volume":"70","author":"L P\u00e9rez-Carbonell","year":"2020","unstructured":"P\u00e9rez-Carbonell L, Lyons E, Gnoni V, et al. Adherence to wakefulness promoting medication in patients with narcolepsy. Sleep Med. 2020;70:50\u20134.","journal-title":"Sleep Med"},{"key":"2532_CR45","doi-asserted-by":"crossref","unstructured":"Gudeman J, Burroughs D. Evidence of accidental dosing errors with immediate-release sodium oxybate: data from the US Food and Drug Administration Adverse Event Reporting System. Drugs Real World Outcomes. 2023. [Epub ahead of print].","DOI":"10.1007\/s40801-023-00351-9"},{"issue":"Suppl 29","key":"2532_CR46","first-page":"S2222","volume":"92","author":"Y Dauvilliers","year":"2022","unstructured":"Dauvilliers Y, Roth T, Bogan R, et al. Efficacy of once-nightly sodium oxybate (ONSXB; FT218) by narcolepsy type: post-hoc analyses from the REST-ON trial. Ann Neurol. 2022;92(Suppl 29):S2222.","journal-title":"Ann Neurol"},{"issue":"4","key":"2532_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.5664\/jcsm.26368","volume":"1","author":"Xyrem International Study Group","year":"2005","unstructured":"Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391\u20137.","journal-title":"J Clin Sleep Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02532-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02532-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T05:18:07Z","timestamp":1686806287000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02532-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,27]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["2532"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02532-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,27]]},"assertion":[{"value":"29 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}